Tarsus Pharma Files 8-K for Regulation FD Disclosure

Ticker: TARS · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1819790

Tarsus Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyTarsus Pharmaceuticals, Inc. (TARS)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance, 8-K

TL;DR

**Tarsus Pharma filed a standard 8-K, mostly for compliance, nothing major to report.**

AI Summary

Tarsus Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibits. This filing indicates that Tarsus, a Delaware-incorporated company with its business address at 15440 Laguna Canyon Road, Irvine, CA, is an emerging growth company. For investors, this matters because it signals that the company is adhering to its disclosure obligations, but the filing itself doesn't contain new material financial or operational news that would directly impact stock price, beyond standard compliance.

Why It Matters

This filing is a routine compliance update, confirming Tarsus Pharmaceuticals, Inc. is meeting its regulatory disclosure requirements as an emerging growth company. It doesn't contain new financial or operational news that would immediately move the stock.

Risk Assessment

Risk Level: low — This 8-K is a routine regulatory filing and does not introduce new risks or significant changes to the company's operations or financial standing.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate new catalysts or risks. Further research into Tarsus Pharmaceuticals, Inc. should focus on their product pipeline, clinical trial results, and financial performance rather than this specific 8-K.

Key Numbers

  • 2024-01-08 — Date of Report (The date of the earliest event reported in the 8-K filing.)
  • 001-39614 — Commission File Number (The SEC file number for Tarsus Pharmaceuticals, Inc.)
  • 81-4717861 — IRS Employer Identification No. (The IRS number for Tarsus Pharmaceuticals, Inc.)

Key Players & Entities

  • Tarsus Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
  • Delaware (company) — state of incorporation for Tarsus Pharmaceuticals, Inc.
  • 001-39614 (dollar_amount) — Commission File Number for Tarsus Pharmaceuticals, Inc.
  • 81-4717861 (dollar_amount) — I.R.S. Employer Identification No. for Tarsus Pharmaceuticals, Inc.
  • 15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618 (company) — principal executive offices address for Tarsus Pharmaceuticals, Inc.
  • (949) 409-9820 (dollar_amount) — telephone number for Tarsus Pharmaceuticals, Inc.
  • TARS (company) — trading symbol for Tarsus Pharmaceuticals, Inc. Common Stock
  • The Nasdaq Stock Market LLC Nasdaq Global Select Market (company) — exchange where Tarsus Pharmaceuticals, Inc. Common Stock is registered

FAQ

What is the primary purpose of this 8-K filing by Tarsus Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing, dated January 8, 2024, is to disclose information under Regulation FD and to file financial statements and exhibits, as indicated in the 'ITEM INFORMATION' section.

What is the trading symbol and exchange for Tarsus Pharmaceuticals, Inc.'s common stock?

The trading symbol for Tarsus Pharmaceuticals, Inc.'s Common Stock, $0.0001 par value per share, is TARS, and it is registered on The Nasdaq Stock Market LLC Nasdaq Global Select Market.

Is Tarsus Pharmaceuticals, Inc. considered an 'emerging growth company'?

Yes, Tarsus Pharmaceuticals, Inc. indicates by check mark that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

What is the state of incorporation for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. is incorporated in Delaware, as stated under 'State or other jurisdiction of incorporation'.

What is the business address and phone number of Tarsus Pharmaceuticals, Inc.?

The business address of Tarsus Pharmaceuticals, Inc. is 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618, and its telephone number is (949) 409-9820.

Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-08 09:00:13

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TARS The Nasdaq Sto

Filing Documents

01 Regulation FD

Item 7.01 Regulation FD. On January 8, 2024, Tarsus Pharmaceuticals, Inc. (the "Company") published a corporate presentation on the Investor & News section of its website, which is filed as Exhibit 99.1 to this Current Report on Form 8-K (the "Report"). The information in this Report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference in any registration statement or other filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Tarsus Pharmaceuticals, Inc. Corporate Presentation . 104 Cover Page Interactive Data File (embedded within XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TARSUS PHARMACEUTICALS, INC. Date: January 8, 2024 /s/ Jeffrey S. Farrow Jeffrey S. Farrow Chief Financial Officer and Chief Strategy Officer (Principal Financial Officer and Principal Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.